Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 with Ibrutinib and Radiation in Relapsed/Refractory B-cell Lymphoma
NCT02927964Phase 2Completed
- Start
- Nov 2016
- Primary completion
- May 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelitolimod in follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). Primary endpoints: Dose-limiting Toxicity up to 24 months and Tumor Response Rates up to 24 months. Started Nov 2016; status: completed.
02
Drugs
nelitolimod
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02927964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927964.